JP2003530431A - ナフタルイミドおよび抗増殖性剤を含有する組成物 - Google Patents

ナフタルイミドおよび抗増殖性剤を含有する組成物

Info

Publication number
JP2003530431A
JP2003530431A JP2001576006A JP2001576006A JP2003530431A JP 2003530431 A JP2003530431 A JP 2003530431A JP 2001576006 A JP2001576006 A JP 2001576006A JP 2001576006 A JP2001576006 A JP 2001576006A JP 2003530431 A JP2003530431 A JP 2003530431A
Authority
JP
Japan
Prior art keywords
naphthalimide
antiproliferative agent
agent
amonafide
antiproliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001576006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530431A5 (enExample
Inventor
デニス・エム・ブラウン
Original Assignee
ケムジェネックス・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケムジェネックス・セラピューティクス・インコーポレイテッド filed Critical ケムジェネックス・セラピューティクス・インコーポレイテッド
Publication of JP2003530431A publication Critical patent/JP2003530431A/ja
Publication of JP2003530431A5 publication Critical patent/JP2003530431A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001576006A 2000-04-12 2001-04-12 ナフタルイミドおよび抗増殖性剤を含有する組成物 Withdrawn JP2003530431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
US60/197,103 2000-04-12
PCT/US2001/012169 WO2001078705A2 (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Publications (2)

Publication Number Publication Date
JP2003530431A true JP2003530431A (ja) 2003-10-14
JP2003530431A5 JP2003530431A5 (enExample) 2008-05-29

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001576006A Withdrawn JP2003530431A (ja) 2000-04-12 2001-04-12 ナフタルイミドおよび抗増殖性剤を含有する組成物

Country Status (10)

Country Link
US (2) US6630173B2 (enExample)
EP (1) EP1274458B1 (enExample)
JP (1) JP2003530431A (enExample)
AT (1) ATE305312T1 (enExample)
AU (1) AU5348301A (enExample)
CA (1) CA2404278C (enExample)
DE (1) DE60113666T2 (enExample)
ES (1) ES2248312T3 (enExample)
HK (1) HK1052874B (enExample)
WO (1) WO2001078705A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
US20040082788A1 (en) * 2002-07-08 2004-04-29 Chemgenex Therapeutics, Inc. Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
WO2004009092A1 (en) * 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
US20050192312A1 (en) * 2004-01-30 2005-09-01 Brown Dennis M. Naphthalimide dosing by N-acetyl transferase genotyping
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
WO2006086693A2 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
US6747061B2 (en) * 2000-03-21 2004-06-08 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物

Also Published As

Publication number Publication date
DE60113666D1 (de) 2005-11-03
ES2248312T3 (es) 2006-03-16
EP1274458B1 (en) 2005-09-28
DE60113666T2 (de) 2006-06-14
ATE305312T1 (de) 2005-10-15
CA2404278A1 (en) 2001-10-25
WO2001078705A2 (en) 2001-10-25
US6630173B2 (en) 2003-10-07
US20020025916A1 (en) 2002-02-28
US20040047918A1 (en) 2004-03-11
HK1052874A1 (en) 2003-10-03
AU5348301A (en) 2001-10-30
EP1274458A2 (en) 2003-01-15
WO2001078705A3 (en) 2002-06-20
HK1052874B (en) 2006-05-04
CA2404278C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
US20110008307A1 (en) Cephalotaxine Alkaloid Compositions and Uses Thereof
US6630173B2 (en) Naphthalimide compositions and uses thereof
AU2001245803A1 (en) Cephalotaxine alkaloid compositions and uses thereof
CN101610776A (zh) 包含CNDAC(2′-氰基-2′-脱氧-N4 -棕榈酰基-1-β-D-阿拉伯呋喃糖基-胞嘧啶)和细胞毒剂的组合
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US20020040011A1 (en) Naphthoquinone compositions and uses thereof
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
US20070207977A1 (en) Naphthalimide compositions and uses thereof
TW201717926A (zh) 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法
AU2006202650B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
AU2001253483B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
US20060211648A1 (en) Naphthalimide compositions and uses thereof
US20020022652A1 (en) Methylnogarol compositions and uses thereof
HK1052138B (en) Cephalotaxine alkaloid combination compositions and uses thereof
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
CN106572992A (zh) 用curaxins进行组合治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080403

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101126